The guidance was developed by a panel of HCV experts in the fields of hepatology and infectious diseases, using an evidence-based review of information that is largely available to healthcare practitioners. The process and detailed methods for developing the guidance are detailed in Methods Table 1. Recommendations were rated according to the strength of the recommendation and quality of the supporting evidence (see Methods Table 2). Commonly used abbreviations are expanded in Methods Table 3.

The panel regularly reviews available data and decides whether a regimen should be classified as recommended, alternative, or not recommended for a particular subgroup of patients. Recommended regimens are those that are favored for most patients in that subgroup, based on optimal efficacy, favorable tolerability and toxicity profiles, duration, and pill burden. Alternative regimens are those that are effective but, relative to recommended regimens, have potential disadvantages, limitations for use in certain patient populations, or less supporting data than recommended regimens. In certain situations, an alternative regimen may be an optimal regimen for a specific patient situation. Not recommended regimens are clearly inferior compared to recommended or alternative regimens due to factors such as lower efficacy, unfavorable tolerability and toxicity, longer duration, and/or higher pill burden. Unless otherwise indicated, such regimens should not be administered to patients with HCV infection.

Last update: 
September 21, 2017